Follow-The-Filings

Security · featured owners

STOK

Stoke Therapeutics Inc. COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 2.1%
  • $30M
  • 1 add 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 2.1% (James Silverman - Opaleye...) · not free-float ownership

  1. James Silverman 2.1%
  2. Nathan Fischel 0.8%
  3. Palo Alto Investors add 0.4%

holders

sorted by % of portfolio · long equity only · exits show last held size · open a manager for their book

history
James Silverman - Opaleye Management 2026 Q2 2.1% Hold 700,000 $23M hist
Nathan Fischel - Dafna Capital Management 2026 Q2 0.8% Hold 130,875 $4M hist
Palo Alto Investors 2026 Q1 stale 0.4% Add +17.5% 84,631 $3M hist
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0% Exit 0.00 pp 9,000 $293K hist

3 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $8.78M $36.56M $184.42M
Gross profit — — —
Gross margin — — —
Net income -$104.7M -$88.98M -$6.88M
Net margin * -1192.5% -243.4% -3.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $215.34M $232.76M $305.7M
Total non-current assets * $13M $38.8M $112.73M
Total assets $228.34M $271.56M $418.43M
Total current liabilities $30.82M $40.06M $57.88M
Total non-current liabilities $37.96M $2.48M $8.1M
Total equity $159.56M $229.02M $352.46M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$81.07M -$86.85M $45.58M
Cash from investing $105.95M -$107.48M -$186.81M
Cash from financing $53.01M $131.09M $97.39M
Net change in cash $77.89M -$63.23M -$43.84M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders